Will Zimulti’s Outlook Be Affected By Suicidality Signal?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will address psychiatric and neurological profiles of Sanofi-Aventis’ rimonabant for weight management.
You may also be interested in...
Merck To Focus Taranabant Development On Lower Dose
Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.
Merck To Focus Taranabant Development On Lower Dose
Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.
Sanofi Withdraws Zimulti NDA For Weight Loss
Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.